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ABSTRACT
Analysis of the roles of the short chain fatty acid receptor, free
fatty acid 3 receptor (FFA3), has been severely limited by the
low potency of its endogenous ligands, the crossover of
function of these on the closely related free fatty acid 2 receptor,
and a dearth of FFA3-selective synthetic ligands. From
a series of hexahydroquinolone-3-carboxamides, we demon-
strate that 4-(furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,
8-hexahydroquinoline-3-carboxamide is a selective and moder-
ately potent positive allosteric modular (PAM)-agonist of the
FFA3 receptor. Modest chemical variations within this series
resulted in compounds completely lacking activity, acting as
FFA3 PAMs, or appearing to act as FFA3-negative allosteric
modulators. However, the pharmacology of this series was
further complicated in that certain analogs displaying overall
antagonism of FFA3 function actually appeared to generate their
effects via a combined positive allosteric binding cooperativity
and negative allosteric effect on orthosteric ligand maximal
signaling response. These studies show that various PAM-agonist
and allosteric modulators of FFA3 can be identified and charac-
terized. However, within the current chemical series, considerable
caremust be taken to define the pharmacological characteristics of
specific compounds before useful predictions of their activity and
their use in defining specific roles of FFA3 in either in vitro and in
vivo settings can be made.
Introduction
A pair of closely related G protein–coupled receptors rec-
ognize and are activated by short chain fatty acids (SCFAs)
produced in the body predominantly through the fermenta-
tion of poorly digestible carbohydrates by the gut microbiota
(Brown et al., 2003; Le Poul et al., 2003; Stoddart et al., 2008b;
Cani et al., 2013). In recent times, these receptors, free fatty
acid 2 receptor (FFA2) (previously designated GPR43) and
free fatty acid 3 receptor (FFA3) (previously GPR41), have
attracted considerable attention, not least because under-
standing of the role of the microbiota in the regulation of
health has developed and deepened (Tan et al., 2014). Indeed,
broad appreciation of the role of the microbiota in areas
including metabolic health and the regulation of inflamma-
tory processes has encouraged detailed analysis of the SCFA
receptors and resulted in suggestions that theymight be novel
and effective therapeutic targets (Ulven, 2012; Hara et al.,
2013; Yonezawa et al., 2013; Tan et al., 2014). To date,
understanding of the specific roles of FFA2 and FFA3 has
been derived mainly from studies of receptor knockout lines of
mice (Maslowski et al., 2009; Sina et al., 2009; Zaibi et al.,
2010; Bjursell et al., 2011; Tolhurst et al., 2012; Bellahcene
et al., 2013; Kim et al., 2013; Kimura et al., 2013). The reliance
on such mouse models to define the individual functions of
FFA2 and FFA3 reflects, at least in substantial part, that both
receptors are activated by the same group of SCFAs (Brown
et al., 2003; Stoddart et al., 2008a,b), that the expression
patterns of the two receptors can overlap (Nøhr er al., 2013),
and that synthetic ligands capable of selectively activating or
inhibiting FFA2 and FFA3 have been limited in availability
and detailed characterization (Hudson et al., 2011). In recent
times, this situation has improved somewhat for FFA2, with
the description and use of both orthosteric agonists and
antagonists (Schmidt et al., 2011; Hudson et al., 2012a,
2013a) as well as a group of phenylacetamide-based ago-
allosteric modulators (Lee et al., 2008; Wang et al., 2010;
Smith et al., 2011). These compounds have subsequently been
used to define the contribution of FFA2 in SCFA-mediated
inhibition of lipolysis (Lee et al., 2008; Hudson et al., 2013a),
release of the incretin GLP-1 from enteroendocrine cells
(Hudson et al., 2013a), and in neutrophil chemotaxis (Vinolo
et al., 2011). In contrast, only two reports to date have
examined the action of a FFA3-selective agonist, AR420626
[N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,
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8-hexahydro-quinoline-3-carboxamide], indicating this compound
produces a modest but significant stimulation of GLP-1 release
from murine colonic crypt cultures (Nøhr et al., 2013) and
inhibits ghrelin secretion from murine gastric ghrelin cells
(Engelstoft et al., 2013). However, recent suggestions of a key
role for FFA3 in mediating the effects of the SCFA propionate
(C3) on allergic inflammation (Trompette et al., 2014) have
further heightened the need to identify and characterize FFA3-
selective compounds.
In this study, we describe the characterization of ligands
reported in the patent literature to have activity at FFA3
(Leonard et al., 2006), and of some analogs of these. A number
of moderately potent ligands were identified that either
activate this receptor as allosteric agonists, act as positive
allosteric modulators (PAMs) of the effect of SCFAs at the
receptor without detectable direct agonism, or inhibit the
effects of SCFAs in a noncompetitive manner as negative
allosteric modulators (NAMs). Although the detailed phar-
macology of this group of ligands is shown to be complex,
careful selectionmay provide useful tool compounds to further
define the role of FFA3 in both human and rodent cells and
tissues.
Materials and Methods
Materials and Compounds. Tissue culture reagents were from
Life Technologies (Paisley, UK). Compounds 1–8 were synthesized
as described in the supplemental information (Supplemental
Methods). The radiochemical [35S]GTPgS was from PerkinElmer
Life and Analytical Sciences (Beaconsfield, Buckinghamshire, UK).
All other experimental reagents were from Sigma-Aldrich (Poole,
UK).
Cell Culture and Transfection. All cells used in these experi-
ments were derived from Flp-In T-REx 293 cells designed to express
the desired receptor on demand following induction with the
antibiotic doxycycline. All cells used in these studies were previously
described and designed to express either human, mouse, or rat FFA3
(Hudson et al., 2012a); human (h)FFA2 (Stoddart et al., 2008a); or
mutated forms of hFFA3 (Stoddart et al., 2008a). In all cases, the
receptor construct expressed was fused in frame to enhanced yellow
fluorescent protein (eYFP) at its C terminal. The cells were
maintained in Dulbecco’s modified Eagle’s medium without sodium
pyruvate, supplemented with 10% (v/v) fetal bovine serum and
penicillin/streptomycin mixture (Sigma-Aldrich) in a humidified
atmosphere containing 5% CO2. To induce receptor expression, cells
were incubated overnight with 100 ng/ml21 doxycycline.
[35S]GTPgS Incorporation Assay. Cell membrane preparations
were first generated as described previously (Stoddart et al., 2008a).
[35S]GTPgS-binding experiments were then performed using a de-
scribed method (Smith et al., 2011). Briefly, cell membrane prepara-
tions were added to assay buffer (50 mM Tris-HCl, pH 7.4, 10 mM
MgCl2, 100 mM NaCl, 1 mM EDTA, 1 mM GDP, and 0.1% fatty acid-
free bovine serum albumin) containing the appropriate concentra-
tions of ligand and allowed to reach equilibrium by preincubating for
15 minutes at 25°C. [35S]GTPgS was then added to initiate the assay,
before incubation for 1 hour at 25°C. The reaction was terminated by
filtration through GF/C glass-fiber filters, and unbound [35S]GTPgS
was washed from the filters with ice-cold wash buffer (50 mM Tris-
HCl, pH 7.4, and 10mMMgCl2) before the remaining [
35S]GTPgSwas
quantified by liquid scintillation spectrometry.
Extracellular Signal-Regulated Kinase 1/2 Phosphorylation
Assay. Phosphorylation of extracellular signal-regulated kinase
(pERK)1/2 was assessed using a previously described protocol
(Hudson et al., 2012b). Briefly, 80,000 cells were seeded per well in
a 96-well plate, allowed to attached, before incubating overnight with
doxycycline (100 ng/ml21) to induce receptor expression. Cells were
then incubated in serum-free Dulbecco’s modified Eagle’s medium for
5–6 hours prior to the assay. Test compounds were added to the cells
and incubated for 5 minutes at 37°C before cells were lysed and
assayed for pERK1/2 using an Alphascreen-based detection kit
according to the manufacturer’s protocol (Perkin Elmer, Beaconsfield,
Buckinghamshire, UK).
cAMPAssay. cAMPexperimentswere performed using a homoge-
nous time-resolved fluorescence resonance energy transfer-based
detection kit (CisBio Bioassays, Codolet, France), according to the
manufacturer’s protocol. Cells already induced to express the desired
receptor were plated in low-volume 384-well plates, and the inhibition
of 5 mM forskolin-stimulated cAMP production was assessed following
a 30-minute coincubation with test compounds.
Data Analysis and Curve Fitting. All data presented represent
mean6 S.E. of at least three independent experiments. Data analysis
and curve fitting were carried out using the GraphPad Prism soft-
ware package v5.0b. Concentration-response data were fit to three-
parameter sigmoidal concentration-response curves. Global curve
fitting of allosterism data was carried out using the following op-
erational model equation described previously (Keov et al., 2011;
Smith et al., 2011):
E5
EmðtA½AðKB1ab½BÞ1tB½BKAÞn
ð½AKB1KAKB1 ½BKA1a½A½BÞn1ðtA½AðKB1ab½BÞ1tB½BKAÞn
where E is the measured response, and A and B represent the
orthosteric and allosteric ligands, respectively. In this equation, Em is
the maximal system response, a is a measure of the allosteric
cooperativity on ligand-binding affinity, and b is an empirical
measure of the allosteric effect on efficacy. KA and KB are measures
of the binding affinities of the orthosteric and allosteric ligands,
respectively. The value n represents the slope factor of the trans-
duction function, whereas the abilities of the orthosteric and allosteric
ligands to directly activate the receptor are incorporated through the
values tA and tB. To fit experimental data to this equation, in all cases
the system maximum (Em) and slope (n) functions were constrained,
allowing for estimations of a, b, tA, tB, KA, and KB. To fit the data
presented in Figs. 7B, 8B, 9B, and 9C, the KA value for C3 was
constrained to the average value obtained in the experiments
presented in Fig. 4 (summarized in Table 1). Finally, it was also
required that the value for tB be constrained to a value of effectively
0 to fit data for allosteric modulators that did not produce any direct
agonism on their own (compounds 4 and 6).
Results
Based on a patent disclosing synthetic ligands as regulators
of the FFA3 receptor, we initially synthesized the represen-
tative compound 1 (4-(furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide) (Fig. 1). FFA3
is known to couple to the Gi family of heterotrimeric G
proteins (Brown et al., 2003; Le Poul et al., 2003; Stoddart
et al., 2008a,b). In [35S]GTPgS-binding assays performed on
membranes of Flp-In T-Rex 293 cells that had been induced to
express a C-terminally eYFP-tagged form of hFFA3, com-
pound 1 increased incorporation of this radionucleotide in
a concentration-dependent fashion with pEC50 of 5.65 6 0.07
(Fig. 2A). In this assay, 1 produced a maximal response
similar to the endogenous SCFA propionate (C3) but was
approximately 100-fold more potent (pEC50 for C3 5 3.47 6
0.09). These effects of both 1 and C3 reflected interactions
with hFFA3, as no significant response to either ligand was
observed usingmembranes derived from the cells that had not
been pretreated with doxycycline to induce hFFA3-eYFP
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expression (Fig. 2A). Furthermore, 1 was highly selective for
hFFA3 over the closely related hFFA2 receptor because this
compound did not increase [35S]GTPgS incorporation in
membranes of Flp-In TREx 293 cells induced to express
hFFA2-eYFP, although C3 did generate the expected re-
sponse (pEC50 5 4.18 6 0.16) (Fig. 2B). In addition to
stimulating [35S]GTPgS incorporation, compound 1 also
produced similar signaling responses to those of C3 in other
endpoint measures of hFFA3 function in cells induced to
express hFFA3-eYFP. These included inhibition of forskolin-
stimulated cAMP production (Fig. 2C), with pEC50 values of
5.77 6 0.05 and 4.58 6 0.09 for 1 and C3, respectively, and
pERK1/2 (Fig. 2D): pEC50 values of 5.27 6 0.16 for compound
1 and 3.68 6 0.13 for C3. As in the [35S]GTPgS incorporation
assay, in both cAMP and pERK1/2 assays 1 produced similar
maximal responses to that of C3.
It has previously been established that the carboxylic acid
functional group of C3 and other SCFAs are integral to their
function at FFA3, forming key ionic interactions with arginine
residues at positions 5.39 and 7.35 [numbering system of
Ballesteros and Weinstein (1995)] (Stoddart et al., 2008a).
However, compound 1 does not contain a carboxylic acid
functional group, nor a negatively charged carboxylic acid
bioisostere. We assessed, therefore, whether 1 functioned as
an orthosteric ligand for hFFA3. It did not: althoughmutation
to Ala of either Arg5.39 or Arg7.35 completely eliminated
response to C3 in the [35S]GTPgS-binding assay (Fig. 3A), at
both of these mutants the function of 1 was essentially
unaltered (Fig. 3B). It is also important to note that both the
R5.39A and R7.35A mutants of hFFA3-eYFP were expressed
effectively from the inducible locus of stable Flp-In TREx 293
lines, yielding 137 6 5 and 179 6 4% of wild-type hFFA3-
eYFP levels, respectively, as measured by eYFP fluorescence
(Fig. 3C).
The above results suggested that 1 most likely functioned
as an allosteric agonist of hFFA3, binding to a site distinct
from that occupied by the endogenous SCFA agonists. Such
allosteric agonists are often also found to act as allosteric
modulators, exhibiting binding cooperativity or altering
the maximal response of orthosteric agonists (Smith et al.,
2011; Hudson et al., 2013b), and such compounds are of-
ten described as PAM-agonists. As measured in functional
assays, these allosteric effects will manifest in alterations
in the measured potency or maximal signaling response to
the orthosteric ligand when the allosteric modulator is
present. Indeed, coaddition of concentrations of 1 ranging
from 100 nM to 10 mM resulted in observed increases in both
the potency and maximal signaling response for C3 in the
[35S]GTPgS-binding assay (Fig. 4A), suggesting that 1 is
a PAM-agonist of hFFA3. Reciprocal studies showed that
increasing concentrations of C3 (30 mM to 3 mM) also
enhanced the measured potency and maximal signaling
response of 1 (Fig. 4B). Global analyses of the data were
performed using an operational model of allosteric modula-
tion, as described previously (Keov et al., 2011; Smith et al.,
2011). This led to estimations of allosteric effects on binding
cooperativity (loga) and modulation of the maximal signal-
ing response (logb) between C3 and 1; estimates of the ability
of C3 and 1 to directly activate hFFA3 (logtA and logtB); as
well as estimates of the affinities of these two ligands for the
receptor (pKA and pKB) (Table 1). These analyses demon-
strated reciprocal allosteric modulation between C3 and 1
that is primarily attributed to a positive binding coopera-
tivity (a values of 20 and 16 for the reciprocal experiments),
although some positive modulation of the maximal response
was also indicated (b values of 1.7 and 2.8 for the reciprocal
experiments). It is important to note that similar values
were obtained for a in each data set regardless of whether C3
or 1 was treated as modulator, as this value is expected to be
conserved due to the reciprocal nature of allosterism (Keov
et al., 2011). In contrast, the values for b need not be
conserved, in large part because this value is expected to
Fig. 1. Chemical structure of compounds used in this study.
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depend on the intrinsic efficacy of the modulator ligand, and
therefore is predicted to track with changes in the t value of
the modulator (Keov et al., 2011). However, in this case,
given that the tA and tB values were similar (average tA 5
2.3 and tB5 1.8), it is not surprising that similar values were
obtained for b in the reciprocal experiments.
To extend these studies, comparable reciprocal allosterism
experiments were also performed in the cAMP (Fig. 4, C and
D) and pERK1/2 (Fig. 4, E and F) assays. In these experi-
ments, similar response patterns were observed, and global
fitting of these data indicated that again C3 and 1 exhibited
positive binding cooperativity and, to a lesser degree, en-
hancement of each other’s maximal responses (Table 1). In
both cases, there were no statistical differences between the
a values in reciprocal experiments, as would be predicted.
Interestingly, although the largest b value was observed for
the modulation of 1 on C3 function in the cAMP assay (b 5
5.6), this does appear to track with the observed t values as
the largest average t value was indeed observed for 1 in the
cAMP assay (average tB 5 2.8). Similarly, the smallest
average t value was obtained for C3 in the pERK1/2 assay
(average t 5 1.6) and, as would be predicted from this, C3
modulation of 1 in this assay also yielded the lowest value for
b (1.4). A more complete analysis suggested that the average
t value obtained within an assay for the compound used as
a modulator did correlate extremely well with the correspond-
ing estimated b values in the same assay (Supplemental Fig.
1). Together, these results suggest that, although some
differences are observed between ligands and across assays
in the values for b, these differences can be attributed to
differences in the intrinsic efficacy of the ligands and do not
appear to represent bias in the allosteric modulation of FFA3.
Combined ab values are often reported as a means to
measure the overall cooperativity between orthosteric and
allosteric ligands, taking into account both the allosteric
effects on binding cooperativity and maximal response
(Smith et al., 2011). Whereas analysis of these values with
C3 and 1 did show some differences between assays (Table 1),
again, given that statistically similar values were obtained for
a, and b values were found to track withmodulator t value, the
assay differences observed in ab cannot be attributed to bias
modulation.
In addition to estimates of the degree of allosterism and
agonist activity of C3 and 1, global fitting of the allosterism
experiments also provided estimates of the affinities of
these two ligands (Table 1). As would be expected, these val-
ues were generally very similar across each assay and agonist/
modulator combination, yielding an average pKA for C3 of
3.276 0.15 and an average pKB for 1 of 5.016 0.16. Given the
difficulties in developing binding assays for the FFA class of
receptors (Hudson et al., 2011), such estimations may be
Fig. 2. Compound 1 is a selective activator of hFFA3. The concentration
response of 1 to stimulate [35S]GTPgS incorporation into membranes
from cells either induced, or not (2Dox) to express hFFA3-eYFP is
shown in (A). The effects of C3 and 1 in the [35S]GTPgS assay on
membranes from cells expressing hFFA2-eYFP are in (B). Concentration
responses for C3 and 1 showing inhibition of forskolin-stimulated cAMP
production (C) and pERK1/2 (D) were generated from cells induced to
express hFFA3-eYFP.
Fig. 3. Compound 1 is an allosteric agonist of hFFA3. The capacity of C3
(A) and compound 1 (B) to promote binding of [35S]GTPgS to each of wild-
type, R5.39A, and R7.35A hFFA3-eYFP is shown. (C) As defined by levels
of eYFP fluorescence, both R5.39A and R7.35A hFFA3-eYFP were
expressed more highly than the wild-type receptor.
Complex Pharmacology of FFA3 Receptor Ligands 203
 at A
SPET Journals on February 14, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
particularly useful in predicting the affinity of ligands for the
FFA3 receptor.
We have previously noted marked differences in effective-
ness of a number of synthetic FFA2 ligands between species
orthologs (Hudson et al., 2012a,b; Hudson et al., 2013a) and
next, therefore, assessed the activity of 1 at both rat and
mouse (m) orthologs of FFA3 (mFFA3). In the [35S]GTPgS-
binding assay, as anticipated from our previous work (Hudson
et al., 2012a), C3 was significantly more potent at both rat
FFA3 (pEC50 5 4.82 6 0.13) and mFFA3 (pEC50 5 5.25 6
0.10) than at hFFA3 (3.47 6 0.09) (Fig. 5A). In contrast, 1
displayed modestly reduced potency at the rodent orthologs
(pEC50 5.27 6 0.08 for rat, and 5.20 6 0.07 for mouse)
compared with its potency at the human receptor (5.656 0.07)
(Fig. 5B). Given that 1 was found to be a PAM-agonist of
hFFA3, we next assessed whether this allosteric modulation
of C3 by 1 was also observed at mFFA3. For this we generated
concentration-response curves to C3 in the presence of
increasing concentrations of 1 (Fig. 5C), as well as reciprocal
experiments generating concentration-response curves to 1 in
the presence of increasing concentrations of C3 (Fig. 5D).
Global curve fit analysis of these data was performed, and the
resulting estimated parameters are shown in Table 2. Indeed,
through these reciprocal experiments, positive binding coop-
erativity was observed and with nearly identical values for a
(Table 2). However, the values for a obtained were lower than
those observed for hFFA3, suggesting the allosteric coopera-
tivity is not as strong at mFFA3 as it is at hFFA3. However, as
was the case with hFFA3, some positive allosteric modulation
of the maximum signaling response was also observed with
mFFA3, and again the magnitude of this correlated with the
observed t value for the modulator. Specifically, 1 displayed
a lower average t value (average tB 5 1.3) than C3 (average
tA 5 1.9) in the cAMP assay at mFFA3 and, as would be
predicted from this, also yielded a lower b value when used as
the modulator (b 5 2.1) than did C3 (b 5 4.2). It was also
interesting to note that the average affinities between these
reciprocal experiments at mFFA3 suggest a pKA of 4.41 for C3
and pKB of 4.74 for 1. Comparison of these values with those
obtained for hFFA3 (Fig. 4; Table 1) demonstrated that,
Fig. 4. Compound 1 is a PAM-agonist of hFFA3. Various fixed concentrations of 1 were added to concentration-response assays for C3 in each of
[35S]GTPgS binding (A), cAMP inhibition (C), and pERK1/2 activation (E) studies. Reciprocal experiments in which various fixed concentration of C3 was
added to concentration-response curves for compound 1 are shown for [35S]GTPgS binding (B), cAMP inhibition (D), and pERK1/2 (F). See text and tables
for details of the curve fit analyses.
TABLE 1
Operational model analysis of C3 and compound 1 at hFFA3
[35S]GTPgS cAMP pERK1/2
Agonista C3 1 C3 1 C3 1
Modulatorb 1 C3 1 C3 1 C3
loga 1.30 6 0.16 1.21 6 0.13 1.11 6 0.31 1.70 6 0.27 1.34 6 0.16 1.40 6 0.19
logb 0.23 6 0.07 0.44 6 0.04 0.75 6 0.12 0.28 6 0.09 0.31 6 0.06 0.16 6 0.07
logtA
c 0.30 6 0.05 0.42 6 0.05 0.05 6 0.05 0.34 6 0.09 0.31 6 0.04 0.03 6 0.07
logtB
d 0.06 6 0.02 0.40 6 0.05 0.45 6 0.16 0.44 6 0.10 0.10 6 0.05 0.33 6 0.05
pKA
c 3.16 6 0.11 3.18 6 0.09 3.96 6 0.16 3.41 6 0.18 2.96 6 0.08 2.97 6 0.09
pKB
d 5.86 6 0.07 4.92 6 0.08 5.15 6 0.17 4.85 6 0.18 4.92 6 0.10 4.84 6 0.13
ab 34 44 72 95 44 50
aAgonist is the compound used to generate concentration-response information.
bModulator is the compound used in fixed concentrations.
ctA and pKA are values estimated for C3.
dtB and pKB are values estimated for 1.
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although 1 does show slightly reduced affinity for mFFA3
compared with hFFA3, C3 appears to have significantly
higher affinity for the mouse ortholog than it has for the
human. Both of these assessments are in good agreement with
the relative potency of these compounds in functional assays
at mFFA3 compared with hFFA3 (Fig. 5, A and B).
The Arena Pharmaceuticals patent (Leonard et al., 2006)
lists 14 ligands designated as either agonists or antagonists of
FFA3. To explore the structure-activity relationship (SAR)
and extend the pharmacology of compound 1, we next
explored the functions of an additional reported agonist 2
and an antagonist 3 (see Fig. 1 for compound structures) at
hFFA3-eYFP in the [35S]GTPgS-binding assay (Fig. 6A;
Table 3). The 3-furyl analog 2 showed increased maximal
signaling response but reduced potency, whereas 3, carrying
a 4-phenoxyphenyl in the place of the furyl, did not exhibit
significant activity on its own, in agreement with its
purported antagonist activity. To further examine the SAR,
2-bromophenyl (4), 3-biphenyl (5), 3-phenoxyphenyl (6), and
4-biphenyl (7) analogs were assessed (Fig. 6B; Table 3). Among
this series, whereas the 4-biphenyl substituted 7 retained full
agonist activity, although with lower potency, the 3-biphenyl
compound 5 showed reduced maximal signaling response, and
the two phenoxyphenyl compounds (3, 6) and the 2-bromophenyl
4 were essentially inactive. We also synthesized AR420626 (8),
which is identical to 1 apart from a 2,5-dichlorophenyl terminal
ring and is reported to have pEC50 values of 6.57 and 6.92 in
inositol phosphate accumulation and cAMP assays, respectively
(Engelstoft et al., 2013; Nøhr et al., 2013). We found 8 to be a full
agonist with potency resembling 1 (pEC50 5 5.74 6 0.11) in the
[35S]GTPgS-binding assay (Fig. 6C).
Analysis of the analogs tested failed to identify any
compounds with significantly improved potency compared
with 1. Indeed, across the series there were only relatively
modest differences in potency among compounds that dis-
played agonism (Table 3). There were, however, compounds
producing varying maximal responses, including two that
appeared to be superagonists (2, 7), and another that was
a partial agonist of hFFA3 (5). Considering this partial
agonist, we next assessed whether 5 also allosterically
modulated C3 function at hFFA3, as this might suggest the
compound series could also be used to identify pure allosteric
modulators of FFA3 that do not possess intrinsic efficacy. For
this, we first confirmed the function of 5 in the pERK1/2
assay, in which, as in the [35S]GTPgS assay, it acted as a weak
partial agonist (pEC50 5 5.08 6 0.40; EMax 5 24 6 8%) (Fig.
7A). Interestingly, 5 was also a strong PAM of C3 function in
this assay. However, unlike compound 1 that primarily
increased the potency of C3 (Fig. 4E), 5 significantly increased
the maximal response of C3 with little apparent effect on
potency (Fig. 7B). Global curve fitting of these data confirmed
this observation, indicating a loga value of only 0.11 6 0.29,
Fig. 5. Compound 1 displays similar function at human and rodent orthologs of FFA3. The orthosteric agonist C3 is more potent at rat (r) andmouse (m)
orthologs of FFA3 than at the human receptor (A). By contrast, compound 1 displays similar potency at these species orthologs (B). The effects of adding
various fixed concentrations of 1 to the concentration response of C3 were assessed in the cAMP assay (C). Reciprocal experiments using fixed
concentrations of C3 are also shown (D).
TABLE 2
Operational model analysis of C3 and compound 1 at mFFA3
Agoa Modb loga logb tA
c tB
d pKA
c pKB
d
C3 1 0.64 6 0.36 0.32 6 0.14 0.31 6 0.05 0.29 6 0.16 4.40 6 0.11 4.96 6 024
1 C3 0.65 6 0.27 0.62 6 0.14 0.24 6 0.06 20.18 6 0.11 4.42 6 0.21 4.51 6 0.10
aAgo is the compound used to generate concentration-response information.
bMod is the compound used in fixed concentrations.
ctA and pKA are values estimated for C3.
dtB and pKB are values estimated for 1.
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but a logb of 1.33 6 0.21 for the allosteric effect of 5 on C3,
suggesting that 5 has little positive binding cooperativity with
C3, but does positively enhance the C3 signaling response in
this assay. These analyses also were used to estimate the
affinity of 5, indicating a pKB value of 3.95 6 0.18.
The strong allosteric modulation of C3 by 5, despite this
compound displaying limited agonist activity, suggested that
compounds appearing to be inactive when tested as agonists
might, in fact, be allosteric modulators if they still bind to the
allosteric site of hFFA3. To explore this, we first examined the
effect of a single high concentration (100 mM) of the reported
antagonist 3 as well as the two additional inactive com-
pounds, 4 and 6, on the concentration response to C3 in the
[35S]GTPgS assay (Fig. 8A). In these experiments, 3 largely
eliminated response to C3, as did 6, suggesting that the
compounds were most likely NAMs of hFFA3. By contrast, 4
enhanced the potency of the C3 response without altering
maximal response and, therefore, appeared to act as a PAM of
C3. To explore this in further detail, increasing concentra-
tions of 4 were used in combination with C3 concentration-
response curves (Fig. 8B). Global fitting of these data to the
operational model of allosterism indicated that compound 4
has a pKB of 5.43 6 0.17. Furthermore, these analyses
confirmed a modest but positive binding cooperativity
between C3 and 4 (loga 5 0.79 6 0.10), with effectively no
modulation of themaximal C3 signaling response (logb5 0.086
0.05). Although this represents only modest cooperativity
between compound 4 and C3, it does suggest that this com-
pound may well be a promising lead to develop further and
more effective PAMs of hFFA3.
Next, we explored further details of the two compounds that
in the initial studies appeared to be FFA3 NAMs, 3 and 6. We
generated C3 concentration-response curves in the presence
of increasing fixed concentrations of either 3 (Fig. 9A) or 6
(Fig. 9B) in the [35S]GTPgS-binding assay. In each case, there
was a clear concentration-dependent decrease in the C3
maximal response (but not potency), suggesting that com-
pounds 3 and 6 are indeed NAMs of C3. Global curve fitting of
the data for compound 6 yielded a pKB for this compound of
5.46 6 0.38. Interestingly, the a and b values generated from
these analyses suggested that, whereas a negative effect on
the signaling response was observed (logb 5 21.92 6 0.20),
a positive binding cooperativity (loga 5 1.20 6 0.39) was also
observed between C3 and compound 6. As this was a some-
what surprising result, we also examined the allosteric effects
of 6 on C3 in the pERK1/2 assay, which yielded a similar
pattern of responses to C3 in the presence of compound 6 (Fig.
9C). Once more, whereas the most striking observation was
a clear inhibition of C3 maximal response by 6, the global
curve fit analyses demonstrated that this resulted from
a combination of a negative allosteric b (logb 5 21.88 6
0.25) and a positive allosteric a (loga 5 0.98 6 0.07). As
a means to depict the apparently divergent effects on C3
maximal signaling response and potency produced by com-
pound 6 in the pERK1/2 assay, measures of these two
parameters (EMax and pEC50) obtained from individual
three-parameter concentration-response curve fits to C3 in
the presence of increasing concentrations of 6 were plotted
(Fig. 9D). This clearly demonstrated opposing effects on C3
maximal response and potency by this compound, and that
both effects were produced with near-identical pEC50 values
Fig. 6. Analogs of compound 1 display diverse activity and maximal
signaling response. The concentration-response curves as direct agonists
at hFFA3 in [35S]GTPgS-binding studies of various ligands are shown in
(A–C). Response curves to C3 (A and B) or 1 (C) are shown for comparison
as dashed lines.
TABLE 3
Potency and efficacy of chemical variants of 4-(furan-2-yl)-5-oxo-N-
(o-tolyl)-5,6,7,8-tetrahydroquinoline-3-carboxamide (compound 1)
Compound hFFA3 pEC50
a hFFA3
Efficacyb
C3 3.47 6 0.09 100%
1 5.65 6 0.07 101 6 4%
2 5.24 6 0.08 135 6 8%
3 ,4
4 NR
5 5.70 6 0.43 42 6 8%
6 ,4
7 4.74 6 0.20 132 6 4%
8 (AR420626) 5.74 6 0.11 120 6 4%
NR, no response.
apEC50 values using hFFA3-eYFP in a [
35S]GTPgS-binding assay.
bPercentage of C3 response using hFFA3-eYFP in a [35S]GTPgS-binding assay.
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(5.77 6 0.10 and 5.75 6 0.24, respectively). As would be
predicted, these are similar to the pKB value obtained from
the global curve fit analysis of the [35S]GTPgS data with this
compound (Fig. 9B). Together, these findings indicate that,
although 6 may have initially appeared to be a hFFA3 NAM,
this compound may be better described as a PAM-antagonist,
showing positive binding cooperativity with the orthosteric
ligand, while also negatively modulating orthosteric ligand-
signaling responses.
Finally, as these represent the first compounds described
that could be used as functional antagonists of FFA3, we also
wished to establish whether the negative allosteric effect on
C3 signaling of compound 6 was also observed at the mouse
ortholog of FFA3. To do so, concentration-response curves
were generated to C3 in the pERK1/2 assay in the absence or
presence of a 100 mM concentration of 6 (Fig. 9E). The
presence of 6 at this concentration substantially reduced C3
efficacy to 23 6 7% of the control, suggesting that this
compound may be useful as a functional FFA3 antagonist in
murine systems as well as human.
Discussion
The SCFA receptors FFA2 and FFA3 have generated
increasing interest in recent years, particularly for their roles
linking the microfloral composition of the gut to health (Tan
et al., 2014). Involvement of these receptors has now been
demonstrated in this respect in relation to both metabolism
(Kimura et al., 2013) and inflammation (Trompette et al.,
2014), and this has stimulated interest in the receptors as
novel therapeutic targets (Ulven, 2012; Dranse et al., 2013;
Yonezawa et al., 2013). However, clearly defining the specific
roles of FFA2 versus FFA3, and importantly, which would
ultimately be a more effective therapeutic target in distinct
pathologic conditions, has been challenging in the absence of
selective pharmacological tool compounds. This has been
particularly problematic for FFA3, for which, until recently,
only a single publically available patent describes a series
of FFA3-selective, but poorly characterized, compounds (Leonard
et al., 2006). Recently, a representative compound from this
series, designated AR420626, was used to demonstrate a con-
tribution of FFA3 to SCFA-mediated GLP-1 (Nøhr er al., 2013)
and ghrelin (Engelstoft et al., 2013) secretion. However, the
detailed pharmacology of this compound series had remained
largely unknown. In the present study, we have begun to ex-
plore this by demonstrating that compounds from within this
series act as selective ligands for FFA3 but with varied
pharmacological properties.
Initially, we synthesized and studied 4-(furan-2-yl)-2-
methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-
carboxamide (compound 1) as an exemplar. Although able to
selectively regulate a series of signaling endpoints via hFFA3
with similar maximal responses to the endogenous SCFA C3,
the structure of 1 suggested it was unlikely to be an orthosteric
Fig. 7. The weak partial agonist compound 5 acts as a PAM of C3
activity. The effect of compound 5 as a direct agonist in the pERK1/2
assay was compared with C3 (A). Although a weak partial agonist, 5
acted as a positive allosteric modulator of the efficacy and potency of
C3 (B).
Fig. 8. Analogs of compound 1 display diverse pharmacology, with
compound 4 acting as a hFFA3 PAM. In (A), the effects of single
concentrations of compounds 4, 3, and 6 (100 mM) as allosteric modulators
of C3 function at hFFA3-eYFP in the [35S]GTPgS assay are shown.
Testing the effects of additional concentrations of 4 in this assay (B)
indicates that, although lacking direct agonist activity, 4 is a positive
allosteric modulator of the potency of C3.
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agonist. Indeed, this was confirmed, as 1 still acted as an
effective agonist at forms of hFFA3 in which either of the two
arginine residues known to be key in coordination of the
carboxylate function of SCFAs (Stoddart et al., 2008b) was
mutated. Although 1 was entirely selective for FFA3 over
FFA2, this compound displayed only modest potency for FFA3,
particularly when compared with what had been described
recently for the similar compound AR420626 (Engelstoft et al.,
2013; Nøhr er al., 2013). To establish whether this was related
to intrinsic differences in potency between these two com-
pounds, or instead due to the use of distinct assay systems, we
synthesized AR420626 (compound 8) and found it to have
similar potency to 1 in the [35S]GTPgS assay. This suggests
that, despite lowermeasured potency in this assay, 1 is likely to
be an equally useful selective FFA3 ligand as AR420626.
By extending the SAR of compound 1, we also identified
a number of compounds with activity at FFA3 but with
diverse pharmacological properties. Interestingly, relatively
minor chemical modifications had substantial impact on
ligand function, switching compounds from PAM-agonists,
to PAMs lacking intrinsic agonism, or to PAM-antagonists
having divergent effects on orthosteric ligand potency and
maximal signaling response. Similar observations have been
reported previously, particularly for allosteric modulators of
the metabotropic glutamate receptors, in which these chem-
ical modifications have been described as molecular switches
capable of altering the function of the allosteric ligands (Wood
et al., 2011). The SAR of the FFA3 ligand series suggests that
such switches may also be present among these compounds.
In particular, the presence of either a 2-bromophenyl (4) or
a 3- or 4-phenoxyphenyl (3, 6) substituent on the hexahy-
droquinolone scaffold appears to eliminate intrinsic agonism
of the ligand. In the case of the phenoxyphenyl variants, this
also appears to result in the gain of a negative modulatory
effect on endogenous agonist maximal signaling response.
Although such molecular switches result in a series of
compounds with diverse and interesting pharmacology, they
clearly also complicate ligand optimization and, potentially,
present a significant problem in selecting compounds that
might be used in vivo (Wood et al., 2011).
Another consideration that may complicate the use of these
compounds is that the two compounds identified with
antagonistic properties, 3 and 6, displayed further complexity
in their pharmacology. Specifically, whereas they did nega-
tively modulate C3 maximal signaling response, at the
same time they exhibited positive binding cooperativity with
C3. Similar pharmacology has been observed for allosteric
modulators of other G protein–coupled receptors, with certain
Fig. 9. Compounds 3 and 6 are PAM-antagonists of the
function of C3 at FFA3. Fixed concentrations of compounds
3 (A) and 6 (B, C) were added to concentration-response
curves of propionate (C3) in either [35S]GTPgS-binding (A
and B) or pERK1/2 (C) assays. In (D), effects of 6 on both the
potency (right y-axis) and measured maximal response (left
y-axis) of C3 in pERK1/2 assays are plotted separately to
highlight the separate and distinct allosteric effects of 6 on
the potency and maximal response of C3. Concentration-
response curves to C3 at mouse FFA3-eYFP in the absence
and presence of 100 mM 6 are shown in (E).
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modulators of the CB1 cannabinoid receptor being par-
ticularly notable examples (Price et al., 2005; Baillie et al.,
2013). Indeed, this class of compound might be termed
PAM-antagonists and possess the particularly interesting
property that they should increase the potency of their
antagonism with increasing amounts of orthosteric agonist
present. Whereas this complex pharmacology may complicate
the use of these compounds as tools, as long as they are used
in sufficient concentrations, and under carefully planned
experimental conditions, they should still act effectively
as functional antagonists that will help define further the role
of FFA3.
A further key set of observations within these studies is
that compounds including 1 and 6 are effective regulators of
the mouse ortholog of FFA3 as well as the human receptor.
This is important given that allosteric ligand binding sites
have been predicted to be under less evolutionary pressure
than orthosteric sites and, therefore, less likely to be con-
served across species (Hudson et al., 2013b). Interestingly, the
opposite may be true among the SCFA receptors, in which
significant species differences have been described for both
FFA2 and FFA3 orthosteric ligands (Hudson et al., 2012a,b,
2013a), whereas the function of the allosteric ligands de-
scribed in this study appears more similar across species. This
may result from the nature of the SCFA receptors as
nutritional sensors (Dranse et al., 2013; Milligan et al., 2014)
that respond to ligands derived from fiber fermented by the
gut microbiota. Specifically, as different species rely on
markedly different amounts of fiber in their diet, they are
exposed to significantly different concentrations of SCFAs
(Bergman, 1990). It might then be predicted that the affinity
of these receptors for the endogenous SCFA ligands will also
differ significantly between species (Hudson et al., 2012a).
Indeed, as noted in this study, C3 is substantially more potent
at mouse and rat FFA3 than at the human ortholog, and we
have previously reported on significant variation in SCFA
potency at human, rodent, and ruminant orthologs of FFA2
(Hudson et al., 2012a,b).
Despite some potential challenges, as described above,
members of this series of FFA3 allosteric ligands represent
the best currently available options to selectively target this
receptor pharmacologically. The diverse and complex phar-
macology observed, even within the relatively small number
of analogs explored in detail to date, suggests that further
development of this series may yet provide allosteric
agonists, PAM-agonists, PAMs, NAMs, or PAM-antagonists
for the FFA3 receptor with even more useful pharmacolog-
ical properties.
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Supplemental Methods 
General 
All commercially available starting materials and solvents were used without further purification, unless 
otherwise stated. Toluene was dried over 4Å sieves. Purification by flash chromatography was carried out 
using silica gel 60 (0.040-0.063 mm, Merck). 1H and 13C NMR spectra were calibrated relative to TMS 
internal standard or residual solvent peak. Purity was determined by HPLC. HPLC analysis was performed 
using a Dionex 120 C18 column (5µm, 4.6x150 mm); flow: 1 mL/min; 10% acetonitrile in water (0-1 min), 
10-100% acetonitrile in water (1-10 min), 100% acetonitrile (11-15 min), with both solvents containing 
0.05% TFA or 0.1% HCOOH as modifier; UV detection at 254 nm. High-resolution mass spectra (HRMS) 
were obtained on a Thermo Finnigan TSQ 700 using electrospray ionization (ESI) or a Bruker micrOTOF-Q 
II (ESI).  
General procedure for synthesis of tetrahydroquinolinones (THQ): A vial was added 3-oxobutanamide 
(1 equiv), carbaldehyde (1 equiv), 3-aminocyclohex-2-enone (1 equiv) and IPA (5 mL/mmol) and heated to 
80oC for two-four days. The reaction mixture was concentrated under vacuum and purified by flash 
chromatography. 
3-Oxo-N-(o-tolyl)butanamide 
 A dry flask under argon was added toluene (5 mL), o-toluidine (2.7 mL, 25.4 mmol) and 
2,2,6-trimethyl-4H-1,3-dioxin-4-one (3.4 mL, 25.6 mmol) and heated to 110oC for five 
hours. The reaction was cooled to room temperature, diluted with acetone and concentrated 
with silica before purification by flash chromatography (SiO2, acetone:petroleum ether, 1:4) to give 3.24 g 
(67%) of white needle shaped crystals: tR = 8.58 min (HPLC); 1H NMR (CDCl3) δ 9.16 (s, 1H), 7.90 (d, J = 
8.0 Hz, 1H), 7.24 – 7.15 (m, 2H), 7.10 – 7.01 (m, 1H), 3.61 (s, 2H), 2.32 (s, 6H); 13C NMR (CDCl3) δ 205.8, 
163.5, 135.7, 130.5, 128.8, 126.7, 125.0, 122.5, 49.3, 31.3, 17.9. 
4-(Furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (1) 
The title compound was prepared from 3-oxo-N-(o-tolyl)butanamide (280 mg, 1.47 
mmol) and furan-2-carbaldehyde (122 µL, 1.47 mmol) according to the general 
procedure THQ to give 259 mg (49%) of a pale yellow solid (purity 96.8% by HPLC) 
after purification by flash chromatography (SiO2, EtOAc): tR = 9.87 min (HPLC); 1H 
NMR (CDCl3) δ 7.70 (d, J = 8.0 Hz, 1H), 7.66 (s, 1H), 7.37 – 7.28 (m, 1H), 7.22 – 7.09 
(m, 3H), 7.09 – 6.98 (m, 1H), 6.28 (dd, J = 3.1 Hz, 1.9 Hz, 1H), 6.10 (d, J = 3.2 Hz, 1H), 5.13 (s, 1H), 2.48 – 
2.30 (m, 4H), 2.27 (s, 3H), 2.08 (s, 3H), 2.01 – 1.84 (m, 2H); 13C NMR (CDCl3) δ 195.4, 166.5, 157.1, 152.0, 
142.7, 141.8, 136.1, 130.5, 129.5, 126.5, 124.9, 123.4, 110.7, 108.5, 106.1, 105.2, 36.9, 31.1, 27.2, 21.1, 
18.8, 17.8; ESI-HRMS calcd for C22H22N2O3Na (M+Na+) 385.1523, found 385.1535. 
4-(Furan-3-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (2) 
The title compound was prepared from 3-oxo-N-(o-tolyl)butanamide (190 mg, 0.99 
mmol) and furan-3-carbaldehyde (100 µL, 1.16 mmol, ~ 1.2 equiv) according to the 
general procedure THQ to give 204 mg (57%) of a yellow foam (purity 96.9% by 
HPLC) after purification by flash chromatography (SiO2, EtOAc:petroleum ether, 1:1): 
tR = 10.01 min (HPLC); 1H NMR (CDCl3) δ 7.78 (d, J = 7.9 Hz, 1H), 7.44 – 7.31 (m, 
3H), 7.15 (t, J = 7.7 Hz, 1H), 7.09 (d, J = 7.2 Hz, 1H), 7.00 (dt, J = 7.4, 3.7 Hz, 1H), 6.57 (s, 1H), 6.39 (d, J 
= 0.9 Hz, 1H), 4.95 (s, 1H), 2.46 – 2.27 (m, 4H), 2.35 (s, 3H), 2.01 – 1.82 (m, 2H), 1.87 (s, 3H); 13C NMR 
(CDCl3) δ 195.7, 166.2, 150.8, 143.7, 142.1, 140.0, 136.1, 130.4, 129.2, 128.7, 126.5, 124.6, 122.7, 111.3, 
110.3, 106.3, 36.8, 28.0, 27.3, 21.0, 18.7, 17.1; ESI-HRMS calcd for C22H22N2O3Na (M+Na+) 385.1523, 
found 385.1541. 
4-(2-Bromophenyl)-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (3) 
The title compound was prepared from 3-oxo-N-(o-tolyl)butanamide (167 mg, 1.5 
mmol) and 2-bromobenzaldehyde (278 mg, 1.5 mmol) according to the general 
procedure THQ to give 139 mg (21%) of a bright yellow solid (purity 96% by HPLC) 
after purification by flash chromatography (SiO2, EtOAc:petroleum ether, 1:1): tR = 
10.43 min (HPLC); 1H NMR (CDCl3) δ 7.48 – 7.38 (m, 3H), 7.23 (d, J = 1.2 Hz, 1H), 
7.20 (s, 1H), 7.15 – 7.09 (m, 2H), 7.08 – 6.98 (m, 2H), 6.70 (s, 1H), 5.37 (s, 1H), 2.30 (ddd, J = 8.6, 7.0, 3.1 
Hz, 4H), 2.16 (s, 3H), 1.90 (s, 3H), 1.86 (d, J = 6.8 Hz, 2H); 13C NMR (CDCl3) δ 195.2, 166.6, 151.0, 145.4, 
138.2, 135.5, 133.1, 131.6, 131.1, 130.5, 128.4, 128.2, 126.4, 125.6, 124.6, 122.7, 111.6, 109.5, 38.8, 37.0, 
27.5, 21.0, 18.6, 17.5; ESI-HRMS calcd for C24H24 BrN2O2 (M+H+) 451.1016, found 451.1006. 
4-([1,1'-Biphenyl]-4-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (4) 
The title compound was prepared from 3-oxo-N-(o-tolyl)butanamide (193 mg, 1.01 
mmol) and [1,1'-biphenyl]-4-carbaldehyde (182 mg, 1.00 mmol) according to the 
general procedure THQ to give 147 mg (33%) of a pale yellow foam (purity 95.1% by 
HPLC) after purification by flash chromatography (SiO2, EtOAc): tR = 11.79 min 
(HPLC); 1H NMR (CDCl3) δ 7.75 (d, J = 7.9 Hz, 1H), 7.59 – 7.50 (m, 6H), 7.42 (t, J = 
7.5 Hz, 2H), 7.37 – 7.29 (m, 1H), 7.17 – 7.10 (m, 1H), 7.05 – 6.99 (m, 2H), 6.96 (dt, J = 
7.4, 3.7 Hz, 1H), 6.49 (s, 1H), 5.08 (s, 1H), 2.42 (s, 3H), 2.40 – 2.25 (m, 4H), 2.00 – 
1.78 (m, 2H), 1.64 (s, 3H); 13C NMR (CDCl3) δ 195.5, 166.3, 150.2, 144.1, 141.6, 140.8, 
140.2, 136.0, 130.3, 128.8, 128.7, 127.8, 127.3, 127.0, 126.4, 124.6, 122.8, 112.1, 107.7, 37.2, 37.0, 27.4, 
20.9, 18.8, 17.0; ESI-HRMS calcd for C30H28N2O2Na (M+Na+) 471.2043, found 471.2031. 
2-Methyl-5-oxo-4-(4-phenoxyphenyl)-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (5) 
The title compound was prepared from 3-oxo-N-(o-tolyl)butanamide (192 mg, 1.00 
mmol) and 4-phenoxybenzaldehyde (172 µL, 1.00 mmol) according to the general 
procedure THQ to give 90 mg (19%) of a pale yellow foam (purity 95.6% by HPLC) 
after purification by flash chromatography (SiO2, EtOAc:petroleum ether, 3:2): tR = 
11.75 min (HPLC); 1H NMR (CDCl3) δ 7.75 (d, J = 7.9 Hz, 1H), 7.48 – 7.41 (m, 2H), 
7.36 – 7.28 (m, 2H), 7.18 – 6.91 (m, 9H), 6.32 (s, 1H), 5.02 (s, 1H), 2.47 – 2.25 (m, 7H), 
2.03 – 1.80 (m, 2H), 1.74 (s, 3H); 13C NMR (CDCl3) δ 195.5, 166.2, 157.0, 156.5, 149.9, 
141.6, 139.8, 136.0, 130.3, 129.8, 129.5, 128.6, 126.5, 124.6, 123.4, 122.8, 119.2, 119.0, 
112.4, 107.7, 37.0, 36.7, 27.4, 20.9, 18.8, 17.2; ESI-HRMS calcd for C30H28N2O3Na (M+Na+) 487.1992, 
found 487.1994. 
4-([1,1'-Biphenyl]-3-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (6) 
The title compound was prepared from 3-oxo-N-(o-tolyl)butanamide (193 mg, 1.01 
mmol) and [1,1'-biphenyl]-3-carbaldehyde (170 µL, 1.04 mmol) according to the general 
procedure THQ to give 168 mg (37%) of a pale yellow foam (purity 95.5% by HPLC) 
after purification by flash chromatography (SiO2, EtOAc:petroleum ether, 1:1): tR = 
11.79 min (HPLC); 1H NMR (CDCl3) δ 7.77 – 7.72 (m, 2H), 7.57 – 7.52 (m, 2H), 7.48 – 
7.30 (m, 6H), 7.11 (t, J = 7.7 Hz, 1H), 7.03 (s, 1H), 7.01 – 6.91 (m, 2H), 6.51 (s, 1H), 
5.11 (s, 1H), 2.41 (s, 3H), 2.38 – 2.22 (m, 4H), 1.95 – 1.77 (m, 2H), 1.58 (s, 3H); 13C 
NMR (CDCl3) δ 195.4, 166.3, 150.2, 145.6, 142.0, 141.8, 141.0, 136.1, 130.3, 129.6, 128.8, 128.5, 127.4, 
127.2, 127.0, 126.4, 126.1, 124.5, 122.7, 112.1, 107.6, 37.5, 37.0, 27.4, 20.8, 18.8, 16.9; ESI-HRMS calcd 
for C30H28N2O2Na (M+Na+) 471.2043, found 471.2046. 
2-Methyl-5-oxo-4-(3-phenoxyphenyl)-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (17)  
The title compound was prepared from 3-oxo-N-(o-tolyl)butanamide (191 mg, 1.00 
mmol) and 3-phenoxybenzaldehyde (172 µL, 1.00 mmol) according to the general 
procedure THQ to give 170 mg (37%) of a pale yellow foam (purity 95.7% by HPLC) 
after purification by flash chromatography (SiO2, EtOAc:petroleum ether, 1:1): tR = 
11.81 min (HPLC); 1H NMR (CDCl3) δ 7.72 (d, J = 8.0 Hz, 1H), 7.34 – 7.21 (m, 4H), 
7.19 – 7.05 (m, 4H), 7.01 (s, 1H), 7.00 – 6.93 (m, 3H), 6.83 – 6.76 (m, 1H), 6.40 (s, 1H), 
5.02 (s, 1H), 2.45 – 2.24 (m, 7H), 2.00 – 1.80 (m, 2H), 1.76 (s, 3H); 13C NMR (CDCl3) δ 195.3, 166.2, 158.1, 
156.7, 150.2, 147.3, 141.6, 136.0, 130.4, 130.2, 129.8, 128.8, 126.5, 124.7, 123.5, 123.0, 123.0, 119.0, 118.4, 
117.0, 112.0, 107.6, 37.4, 36.9, 27.4, 20.9, 18.7, 17.3; ESI-HRMS calcd for C30H28N2O3Na (M+Na+) 
487.1992, found 487.1974. 
N-(2,5-dichlorophenyl)-3-oxobutanamide 
In a microwave vial were added 2,5-dichloroaniline (1,14 g, 7.03 mmol) and 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (935 µL, 7.03 mmol). Microwave heating at 160°C was 
applied to the neat reaction mixture for 5 min. The crude product was purified by column 
chromatography (SiO2, acetone:petroleum ether, 1:5), subsequently re-dissolved in hot 
toluene and precipitated using petroleum ether to give 721 mg (41%) as a white powder: tR = 10.58 min 
(HPLC); 1H NMR (CDCl3) δ 9.79 (s, 1H), 8.44 (s, 1H), 7.29 (d, J = 8.5 Hz, 1H), 7.02 (dd, J = 8.5, 1.9 Hz, 
1H), 3.65 (s, 2H), 2.34 (s, 3H); 13C NMR (CDCl3) δ 205.0, 163.8, 135.5, 133.3, 129.9, 124.8, 121.7, 121.5, 
77.5, 77.2, 76.8, 49.4, 31.3; HRMS (ESI) calcd for C10H9Cl2NO2 (M+Na
+) 267.9908, found 267.9900. 
N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide 
(8) 
The title compound was prepared by adding 3-aminocyclohex-2-enone (90 mg, 0.81 
mmol), furan-2-carbaldehyde (67 µL, 0.81 mmol) and N-(2,5-dichlorophenyl)-3-
oxobutanamide (200 mg, 0.81 mmol) to a round-bottom flask. The reactants were 
diluted in isopropyl alcohol (1.23 mL/mmol) and heated to 80°C for 48 h. The crude 
product was evaporated onto celite and purified by column chromatography (SiO2, 
50% ethyl acetate in petroleum ether) to obtain 245 mg (72%) as a beige solid: tR = 11.50 min (HPLC); 1H 
NMR (CDCl3) δ 8.38 (d, J = 2.5 Hz, 1H), 8.22 (s, 1H), 7.30 (d, J = 1.0 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 
6.96 (dd, J = 8.6, 2.5 Hz, 1H), 6.64 (s, 1H), 6.27 (dd, J = 3.1, 1.9 Hz, 1H), 6.14 (d, J = 3.2 Hz, 1H), 5.13 (s, 
1H), 2.51 – 2.42 (m, 3H), 2.39 – 2.29 (m, 4H), 2.07 – 1.90 (m, 2H); 13C NMR (CDCl3) δ 195.4, 166.1, 156.3, 
151.4, 144.0, 142.2, 136.3, 133.2, 129.8, 124.3, 122.0, 121.5, 110.7, 109.3, 106.5, 104.9, 37.0, 30.8, 27.5, 
21.2, 19.3. ESI HRMS cald for C21H18Cl2N2O3 (M+Na+) 439.0592, found 439.0566. 
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Supplemental Figure 1. Modulator τ  values correlate strongly with modulation of signaling response 
parameter β  values between ligands and across assays. Estimated β values are plotted against average 
modulator τ values obtained from the experiments presented in Figure 1. Each data point is labeled: “agonist 
+ modulator; assay”. The correlation coefficient is also shown. 
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